Biogen (BIIB) Prepaid Assets (2009 - 2026)
Biogen (BIIB) posted quarterly Prepaid Assets of $1.2 billion for Q1 2026, up 54.27% year-over-year from $757.3 million in Q1 2025, and up 4.01% on a QoQ basis from $1.1 billion in Q4 2025.
Biogen (BIIB) Prepaid Assets (2009 - 2026) Analysis & Trends
Biogen (BIIB) has reported Prepaid Assets for 18 consecutive years, with $1.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 54.27% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 54.27% YoY), while the FY2025 annual figure was $1.1 billion, up 49.28% from the prior year.
- Prepaid Assets came in at $1.2 billion for Q1 2026 at Biogen, up from $1.1 billion in the prior quarter.
- The five-year high for Prepaid Assets was $1.6 billion in Q2 2022, with the low at $615.3 million in Q2 2024.
- Average Prepaid Assets over 5 years is $1.1 billion, with a median of $974.1 million recorded in 2023.
- Across the five-year window, Prepaid Assets surged 114.26% in 2022 and slumped 45.55% in 2023, its largest moves.
- Year by year, Prepaid Assets stood at $1.4 billion in 2022, then declined by 16.62% to $1.2 billion in 2023, then slumped by 36.34% to $752.5 million in 2024, then surged by 49.28% to $1.1 billion in 2025, then climbed by 4.01% to $1.2 billion in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $1.2 billion, $1.1 billion, and $916.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.17 Bn |
| Dec 31, 2025 | 1.12 Bn |
| Sep 30, 2025 | 916.80 Mn |
| Jun 30, 2025 | 850.60 Mn |
| Mar 31, 2025 | 757.30 Mn |
| Dec 31, 2024 | 752.50 Mn |
| Sep 30, 2024 | 674.00 Mn |
| Jun 30, 2024 | 615.30 Mn |
| Mar 31, 2024 | 1.17 Bn |
| Dec 31, 2023 | 1.18 Bn |
| Sep 30, 2023 | 974.10 Mn |
| Jun 30, 2023 | 895.90 Mn |
| Mar 31, 2023 | 1.41 Bn |
| Dec 31, 2022 | 1.42 Bn |
| Sep 30, 2022 | 1.50 Bn |
| Jun 30, 2022 | 1.65 Bn |
| Mar 31, 2022 | 927.40 Mn |
| Dec 31, 2021 | 740.80 Mn |
| Sep 30, 2021 | 736.30 Mn |
| Jun 30, 2021 | 767.90 Mn |